Zacks Investment Research upgraded shares of PACIFIC BIOSCI (PACB) from NEUTRAL to OUTPERFORM on October 20, 2014, with a target price of $6.00.
Pacific Biosciences of California, Inc. is engaged in the development, manufacture and commercialization of its single molecule, real-time, or SMRT technology-an integrated platform for genetic analysis. The SMRT technology uses the natural processing power of enzymes, combined with specially designed reagents and detection systems, to record individual biochemical events as they occur. The Company's technology platform comprises of the SMRT cells, Phospholinked nucleotides and the PacBio RS (an instrument that conducts, monitors and analyzes single molecule biochemical reactions in real time). Its product will find its application in both research institutions and commercial companies, including genome centers, government and academic institutions, genomic service providers, pharmaceutical companies and agriculture companies. Pacific Biosciences of California, Inc. is headquartered in Menlo Park, California.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PACIFIC BIOSCI (PACB),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment